Literature DB >> 11344045

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.

H L Benford1, N W McGowan, M H Helfrich, M E Nuttall, M J Rogers.   

Abstract

Bisphosphonates inhibit osteoclast-mediated bone resorption by mechanisms that have only recently become clear. Whereas nitrogen-containing bisphosphonates affect osteoclast function by preventing protein prenylation (especially geranylgeranylation), non-nitrogen-containing bisphosphonates have a different molecular mechanism of action. In this study, we demonstrate that nitrogen-containing bisphosphonates (risedronate, alendronate, pamidronate, and zoledronic acid) and non-nitrogen-containing bisphosphonates (clodronate and etidronate) cause apoptosis of rabbit osteoclasts, human osteoclastoma-derived osteoclasts, and human osteoclast-like cells generated in cultures of bone marrow in vitro. Osteoclast apoptosis was shown to involve characteristic morphological changes, loss of mitochondrial membrane potential, and the activation of caspase-3-like proteases capable of cleaving peptide substrates with the sequence DEVD. Caspase-3-like activity could be visualized in unfixed, dying osteoclasts and osteoclast-like cells using a cell-permeable, fluorogenic substrate. Bisphosphonate-induced osteoclast apoptosis was dependent on caspase activation, because apoptosis resulting from alendronate, clodronate, or zoledronic acid treatment was suppressed by zVAD-fmk, a broad-range caspase inhibitor, or by SB-281277, a specific isatin sulfonamide inhibitor of caspase-3/-7. Furthermore, caspase-3 (but not caspase-6 or caspase-7) activity could be detected and quantitated in lysates from purified rabbit osteoclasts, whereas the p17 fragment of active caspase-3 could be detected in human osteoclast-like cells by immunofluorescence staining. Caspase-3, therefore, appears to be the major effector caspase activated in osteoclasts by bisphosphonate treatment. Caspase activation and apoptosis induced by nitrogen-containing bisphosphonates are likely to be the consequence of the loss of geranylgeranylated rather than farnesylated proteins, because the ability to cause apoptosis and caspase activation was mimicked by GGTI-298, a specific inhibitor of protein geranylgeranylation, whereas FTI-277, a specific inhibitor of protein farnesylation, had no effect on apoptosis or caspase activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344045     DOI: 10.1016/s8756-3282(01)00412-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  52 in total

1.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

2.  Genetics of the bone response to bisphosphonate treatments.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 3.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

Review 4.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

5.  Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.

Authors:  H L Neville-Webbe; R E Coleman; I Holen
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

6.  The neurological safety of epidural pamidronate in rats.

Authors:  Pyung Bok Lee; Yong Chul Kim; Chul Joong Lee; Hye Young Shin; Seung Yun Lee; Jong Cook Park; Yun Suk Choi; Chong Soo Kim; Sang Hyun Park
Journal:  Korean J Pain       Date:  2010-05-31

7.  Alendronate reduces osteoclast precursors in osteoporosis.

Authors:  P D'Amelio; A Grimaldi; M A Cristofaro; M Ravazzoli; P A Molinatti; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2009-12-01       Impact factor: 4.507

8.  RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.

Authors:  Karen A Sutherland; Helena L Rogers; Denise Tosh; Michael J Rogers
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

9.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06

10.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

Authors:  P Tassone; P Tagliaferri; C Viscomi; C Palmieri; M Caraglia; A D'Alessandro; E Galea; A Goel; A Abbruzzese; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.